Momelotinib (MMB) Long-Term Safety: Pooled Data from Three Phase 3 Randomized-Controlled Trials (RCTs)
Year: 2022
Type: article
Source: Blood
Authors: Srdan Verstovsek, Ruben Mesa, Vikas Gupta, David Lavie, Viviane Dubruille, Nathalie Cambier, Uwe Platzbecker, Marek Hus, Blanca Xicoy, Stephen T Oh, Jean-Jacques Kiladjian, Alessandro M Vannucchi, Aaron T. Gerds, Miklos Egyed, Jiri Mayer, Tomasz Sacha, Jun Kawashima, Marc Morris, Mei Huang, Claire Harrison
Institutions: The University of Texas MD Anderson Cancer Center, Mays Cancer Center at UT Health San Antonio, University Health Network, Hadassah Medical Center, Centre Hospitalier Universitaire de Nantes, Groupe Hospitalier de l'Institut Catholique de Lille, University Hospital Leipzig, Leipzig University, Medical University of Lublin, Universitat Autònoma de Barcelona, Washington University in St. Louis, Assistance Publique – Hôpitaux de Paris, Hôpital Saint-Louis, Centre d'Investigation Clinique Saint-Louis, University of Florence, Cleveland Clinic, Somogy Megyei Kaposi Mór Oktató Kórház, Masaryk University, University Hospital Brno, St Thomas' Hospital, Guy's and St Thomas' NHS Foundation Trust
Language: English
Subfield: Genetics (clinical)
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4310099778